AKTX Archives - BioTuesdays

Developments

Akari’s nomacopan meets primary and secondary endpoints in Phase 2 bullous pemphigoid trial

Akari Therapeutics’ (NASDAQ:AKTX) nomacopan met its primary safety and secondary efficacy endpoints in a Phase 2 trial of patients with bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease...

May 1, 2020

Developments

Akari reports positive data from long-term Phase 2 nomacopan study

Akari Therapeutics (NASDAQ:AKTX) reported new data from an ongoing, long-term Phase 2 study of nomacopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood...

December 2, 2019

Developments

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...

September 13, 2019

Developments

Akari gets FDA orphan drug designation for nomacopan

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT...

August 30, 2019

Developments

Akari gets FDA fast track designation for nomacopan

Akari Therapeutics (NASDAQ:AKTX) received FDA fast track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT-TMA...

August 14, 2019

Developments

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Akari Therapeutics (NASDAQ:AKTX) reported positive results from the first three bullous pemphigoid (BP) patients in an ongoing Phase 2 clinical trial. BP is a severe orphan inflammatory skin disease characterized by...

April 23, 2019

Developments

Akari Therapeutics announces successful pre-IND FDA meeting for Coversin

Akari Therapeutics (NASDAQ:AKTX) had a positive pre-IND meeting with the FDA about its proposed pivotal clinical trial program for Coversin for the treatment of pediatric hematopoietic stem cell transplant-related...

March 13, 2019

Tag - AKTX

Akari’s nomacopan meets primary and secondary endpoints in Phase 2 bullous pemphigoid trial

Akari reports positive data from long-term Phase 2 nomacopan study

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Akari gets FDA orphan drug designation for nomacopan

Akari gets FDA fast track designation for nomacopan

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Akari Therapeutics announces successful pre-IND FDA meeting for Coversin

General

More